242 related articles for article (PubMed ID: 11311056)
1. Novel peptide conjugates for tumor-specific chemotherapy.
Langer M; Kratz F; Rothen-Rutishauser B; Wunderli-Allenspach H; Beck-Sickinger AG
J Med Chem; 2001 Apr; 44(9):1341-8. PubMed ID: 11311056
[TBL] [Abstract][Full Text] [Related]
2. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
3. Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity.
Rodrigues PC; Roth T; Fiebig HH; Unger C; Mülhaupt R; Kratz F
Bioorg Med Chem; 2006 Jun; 14(12):4110-7. PubMed ID: 16546396
[TBL] [Abstract][Full Text] [Related]
4. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
5. Antagonistic properties of centrally truncated analogs of [D-Trp(32)]NPY.
Balasubramaniam A; Ujhelyi M; Borchers M; Huang Y; Zhai W; Zhou Y; Johnson M; Sheriff S; Fischer JE
J Med Chem; 1996 Mar; 39(5):1142-7. PubMed ID: 8676351
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antitumor activity of 5'-demethyl-5'-trifluoromethyl-daunorubicin and -doxorubicin.
Nakai K; Takagi Y; Ogawa S; Tsuchiya T
Carbohydr Res; 1999 Jul; 320(1-2):8-18. PubMed ID: 10515060
[TBL] [Abstract][Full Text] [Related]
7. Novel daunorubicin-carrier peptide conjugates derived from human calcitonin segments.
Krauss U; Kratz F; Beck-Sickinger AG
J Mol Recognit; 2003; 16(5):280-7. PubMed ID: 14523941
[TBL] [Abstract][Full Text] [Related]
8. Y1 and Y2 receptor selective neuropeptide Y analogues: evidence for a Y1 receptor subclass.
Kirby DA; Koerber SC; May JM; Hagaman C; Cullen MJ; Pelleymounter MA; Rivier JE
J Med Chem; 1995 Oct; 38(22):4579-86. PubMed ID: 7473586
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antitumor activity of 7-O-(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl) daunomycinone derivatives modified at C-3' or C-4'.
Takagi Y; Kobayashi N; Chang MS; Lim GJ; Tsuchiya T
Carbohydr Res; 1998 Feb; 307(3-4):217-32. PubMed ID: 9675364
[TBL] [Abstract][Full Text] [Related]
10. Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution.
Rodrigues PC; Beyer U; Schumacher P; Roth T; Fiebig HH; Unger C; Messori L; Orioli P; Paper DH; Mülhaupt R; Kratz F
Bioorg Med Chem; 1999 Nov; 7(11):2517-24. PubMed ID: 10632061
[TBL] [Abstract][Full Text] [Related]
11. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
[TBL] [Abstract][Full Text] [Related]
12. A new method for chemoselective conjugation of unprotected peptides to dauno- and doxorubicin.
Ingallinella P; Marco AD; Taliani M; Fattori D; Pessi A
Bioorg Med Chem Lett; 2001 May; 11(10):1343-6. PubMed ID: 11392551
[TBL] [Abstract][Full Text] [Related]
13. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives.
Ghirmai S; Mume E; Tolmachev V; Sjöberg S
Carbohydr Res; 2005 Jan; 340(1):15-24. PubMed ID: 15620662
[TBL] [Abstract][Full Text] [Related]
15. Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues.
Kirby DA; Koerber SC; Craig AG; Feinstein RD; Delmas L; Brown MR; Rivier JE
J Med Chem; 1993 Feb; 36(3):385-93. PubMed ID: 8426366
[TBL] [Abstract][Full Text] [Related]
16. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Y3 receptor-mediated synaptic inhibition by chimeric neuropeptide Y-peptide YY peptides in the rat brainstem.
Glaum SR; Miller RJ; Rhim H; Maclean D; Georgic LM; MacKenzie RG; Grundemar L
Br J Pharmacol; 1997 Feb; 120(3):481-7. PubMed ID: 9031753
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antileukemic activity of N-enamine derivatives of daunorubicin, 5-iminodaunorubicin, and doxorubicin.
Stefańska B; Dzieduszycka M; Bontemps-Gracz M; Borowski E; Martelli S
J Antibiot (Tokyo); 1988 Feb; 41(2):193-8. PubMed ID: 3356607
[TBL] [Abstract][Full Text] [Related]
20. Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.
Kirby DA; Boublik JH; Rivier JE
J Med Chem; 1993 Nov; 36(24):3802-8. PubMed ID: 8254609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
